Tmunity Closes $100 Million Funding for T Cell Therapies; Ping An Participates
publication date: Jan 23, 2018
Tmunity Therapeutics, a Philadelphia biopharma developing next-gen immuno-oncology drugs, closed a $100 million Series A round that included Ping An as its first-named investor. Using technology developed at the University of Pennsylvania, Tmunity is developing a broad-based portfolio of T cell therapies for oncology, infectious diseases and autoimmune diseases. Tmunity’s portfolio produces engineered T cells that activate or suppress immunity. Its approaches include T cell receptors, regulatory T cells, Crispr-Cas9 gene editing, allogeneic T cells and bionic T cells, as well as CAR-T programs. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.